Pharmacological Reports (2023) 75:753
https://doi.org/10.1007/s43440-023-00487-z

CORRECTION

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma

Melissa M. Phillips[1,2] · Iuliia Pavlyk[1] · Michael Allen[3] · Essam Ghazaly[4,5] · Rosalind Cutts[6] · Josephine Carpentier[1] · Joe Scott Berry[1] · Callum Nattress[1] · Shenghui Feng[1] · Gunnel Hallden[1] · Claude Chelala[1] · John Bomalaski[7] · Jeremy Steele[2] · Michael Sheaff[8] · Frances Balkwill[3] · Peter W. Szlosarek[1,2]

Published online: 17 May 2023
© The Author(s) 2023

Correction to: Pharmacological Reports (2023)
https://doi.org/10.1007/s43440-023-00480-6

In this article following figures had incorrect units.

1. Figure 3A panel legend has the incorrect units for ADI-PEG20 ("mg/ml" should be "ng/ml")
2. Figure 3D legend says incorrectly "75ong/ml" but should be "750 ng/ml"
3. Figure 4B legend has the incorrect units for argininosuccinate ("mg/ml" but "µg/ml")
4. Figure 7B legend has the incorrect units for the scale bar ("mM" but needs to be "µm")

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

The original article can be found online at https://doi.org/10.1007/s43440-023-00480-6.

✉ Peter W. Szlosarek
p.w.szlosarek@qmul.ac.uk

[1] Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London EC1M 6BQ, UK

[2] Department of Medical Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK

[3] Center for Tumor Microenvironment, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London EC1M 6BQ, UK

[4] Centre for Haemato-Oncology, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London EC1M 6BQ, UK

[5] Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK

[6] Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK

[7] Polaris Pharmaceuticals, Inc., San Diego, CA 92121, USA

[8] Department of Histopathology, Barts Health NHS Trust, Royal London Hospital, London E1 1BB, UK